Hospira Inc.(HSP) has initiated a nationwide voluntary recall of one lot of Hydromorphone Hydrochloride Injection 1 mg/ml, with the knowledge of the FDA, after it was found that the opioid analgesic injection contained more than the intended fill volume.
The recalled product is a prefilled glass cartridge for use with Carpuject Syringe system. The affected lot number is 07547LL, which has an expiration date of July 1, 2013.
The FDA in a statement said that opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), low blood pressure and reduced heart rate including circulatory collapse.
The affected lot was distributed last September and October, initially to wholesalers and a limited number of hospitals in Alaska, Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Indiana, Louisiana, Maryland, Massachusetts, Minnesota, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Tennessee, Texas, Utah, Washington, and Wisconsin.
There have been no reports of adverse events related to the recalled lot, Hospira said.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.